Table 1 Baseline characteristics of the two groups of patients with CF

From: Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

  Cases Controls SMD
N 13 13  
Age (years) 21.03 (5.08) 21.71 (4.12) 0.148
Female sex 8 (61.5%) 8 (61.5%)  < 0.001
BMI (Kg/m2) 20.66 (2.94) 20.96 (1.79) 0.124
Pancreatic insufficiency 11 (100.0%) 12 (92.3%)  
FEV1 (% predicted) 81.89 (20.13) 85.45 (24.31) 0.160
  1. Data are presented as mean (SD) or count (fraction).
  2. SMD standardized mean difference